Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
183 hedge funds and large institutions have $751M invested in Eagle Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 73 reducing their positions, and 14 closing their positions.
113% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.99M
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 180 → 183 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.36% less ownership
Funds ownership: 97.44% → 97.08% (-0.36%)
1% less capital invested
Capital invested by funds: $756M → $751M (-$4.85M)
22% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.2M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$3.22M |
| 3 |
MCM
Matarin Capital Management
New York
|
+$2.36M |
| 4 |
Renaissance Technologies
New York
|
+$2.04M |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$11.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.46M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$5.55M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.45M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.73M |
EGRX Hedge Fund Activity: Q3 2019 in Review
183 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2019, worth a combined $751M — down 0.64% from $756M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EGRX positions and 14 closed out — a net gain of 3 holders — while 57 added to existing stakes and 73 trimmed.
The largest buyer was Credit Suisse, adding an estimated $12.2M. The largest seller was Park West Asset Management, cutting an estimated $11.6M.
- 183 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2019, up from 180 in Q2 2019.
- Funds reported $751M of Eagle Pharmaceuticals, Inc. stock for Q3 2019, down 0.64% quarter-over-quarter.
- 17 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2019 and 14 closed out, a net change of +3 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2019 was Credit Suisse, an estimated $12.2M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2019 was Park West Asset Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2019.